APP and Cognitive impairment: Metformin treatment was shown to inhibit neuronal loss, the direct cause of cognitive deficits in AD, by promoting neurogenesis and inhibiting pathological neuronal apoptosis in the hippocampus of amyloid precursor protein/presenilin-1 (APP/PS1) mice (West et al., 1994; Ou et al., 2018).